Serum endostatin concentrations are higher in men with symptoms of intermittent claudication

Disease Markers

Volumn 2014, Issue , 2014, Pages

  Golledge, Jonathan ^a,b   Clancy, Paula ^a   Hankey, Graeme J ^c,d   Yeap, Bu B ^c,e   Norman, Paul E ^f  

^a JAMES COOK UNIVERSITY   (Australia)

^b TOWNSVILLE HOSPITAL   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d ROYAL PERTH HOSPITAL   (Australia)

^e FREMANTLE HOSPITAL   (Australia)

^f UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOSTATIN; BIOLOGICAL MARKER;

ABDOMINAL AORTA ANEURYSM; AGED; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; HYPERTENSION; INTERMITTENT CLAUDICATION; ISCHEMIC HEART DISEASE; LEG PAIN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SMOKING; WALKING; BLOOD; RISK FACTOR;

AGED; BIOLOGICAL MARKERS; ENDOSTATINS; HUMANS; INTERMITTENT CLAUDICATION; MALE; RISK FACTORS;

EID: 84896979326     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2014/298239     Document Type: Article

References (29)

1. Ng E. L., Weiland T. J., Jelinek G. A., Hadgkiss E., Wilson A., Prevalence of and risk factors for peripheral arterial disease in older adults in an Australian emergency department. Vascular. In press
2. Guerchet M., Aboyans V., Mbelesso P., Mouanga A. M., Salazar J., Bandzouzi B., Tabo A., Clément J. P., Preux P. M., Lacroix P., Epidemiology of peripheral artery disease in elder general population of two cities of Central Africa: Bangui and Brazzaville. European Journal of Vascular and Endovascular Surgery 2012 44 164 169
3. Hirsch A. T., Halverson S. L., Treat-Jacobson D., Hotvedt P. S., Lunzer M. M., Krook S., Rajala S., Hunninghake D. B., The Minnesota Regional Peripheral Arterial Disease Screening Program: toward a definition of community standards of care. Vascular Medicine 2001 6 2 87 96 2-s2.0-0034870788 10.1191/ 135886301701568756
4. McDermott M. M., Greenland P., Liu K., Guralnik J. M., Criqui M. H., Dolan N. C., Chan C., Celic L., Pearce W. H., Schneider J. R., Sharma L., Clark E., Gibson D., Martin G. J., Leg symptoms in peripheral arterial disease associated clinical characteristics and functional impairment. The Journal of the American Medical Association 2001 286 13 1599 1606 2-s2.0-0035802216
5. McDermott M. M., Fried L., Simonsick E., Ling S., Guralnik J. M., Asymptomatic peripheral arterial disease is independently associated with impaired lower extremity functioning: the women's health and aging study. Circulation 2000 101 9 1007 1012 2-s2.0-0034100150
6. McDermott M. M., Carroll T. J., Kibbe M., Kramer C. M., Liu K., Guralnik J. M., Keeling A. N., Criqui M. H., Ferrucci L., Yuan C., Tian L., Liao Y., Berry J., Zhao L., Carr J., Proximal superficial femoral artery occlusion, collateral vessels, and walking performance in peripheral artery disease. JACC Cardiovasc Imaging 2013 6 687 694
7. Seppinen L., Pihlajaniemi T., The multiple functions of collagen XVIII in development and disease. Matrix Biology 2011 30 2 83 92 2-s2.0-79952104610 10.1016/j.matbio.2010.11.001
8. Saarela J., Rehn M., Oikarinen A., Autio-Harmainen H., Pihlajaniemi T., The short and long forms of type XVIII collagen show clear tissue specificities in their expression and location in basement membrane zones in humans. American Journal of Pathology 1998 153 2 611 626 2-s2.0-0031830711
9. Bao Y., Feng W. M., Tang C. W., Zheng Y. Y., Gong H. B., Hou E. G., Endostatin inhibits angiogenesis in hepatocellular carcinoma after transarterial chemoembolization. Hepatogastroenterology 2012 59 1566 1568
10. Bai Y. J., Huang L. Z., Zhou A. Y., Zhao M., Yu W. Z., Li X. X., Antiangiogenesis effects of endostatin in retinal neovascularization. Journal of Ocular Pharmacology and Therapeutics 2012 29 7 10.1089/jop.2012.0225
11. Ling Y., Yang Y., Lu N., You Q.-D., Wang S., Gao Y., Chen Y., Guo Q.-L., Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochemical and Biophysical Research Communications 2007 361 1 79 84 2-s2.0-34547106834 10.1016/j.bbrc.2007.06.155
12. Wu B., Chen H., Shen J., Ye M., Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China. Clinical Therapeutics 2011 33 10 1446 1455 2-s2.0-80054900758 10.1016/j.clinthera.2011.09.016
13. Norman P. E., Flicker L., Almeida O. P., Hankey G. J., Hyde Z., Jamrozik K., Cohort profile: the health in men study (HIMS). International Journal of Epidemiology 2009 38 1 48 52 2-s2.0-60149099915 10.1093/ije/dyn041
14. Iribarren C., Herrinton L. J., Darbinian J. A., Tamarkin L., Malinowski D., Vogelman J. H., Orentreich N., Baer D., Does the association between serum endostatin, an endogenous anti-angiogenic protein, and acute myocardial infarction differ by race? Vascular Medicine 2006 11 1 13 20 2-s2.0-33646164164 10.1191/1358863x06vm654oa
15. Yeap B. B., Alfonso H., Chubb S. A., Handelsman D. J., Hankey G. J., Golledge J., Flicker L., Norman P. E., Lower plasma testosterone or dihydrotestosterone, but not estradiol, is associated with symptoms of intermittent claudication in older men. Clinical Endocrinology 79 5 725 732 10.1111/cen.12208
16. Sun J., Deng L., Duan Y., Chen F., Wang X., Li D., Chen Z., Inhibitory effect of endostatin combined with paclitaxel-cisplatin on breast cancer in xenograft-bearing mice. Experimental and Therapeutic Medicine 2012 3 2 159 164 2-s2.0-84855391831 10.3892/etm.2011.384
17. Braga M. D. S., Chaves K. B., Chammas R., Schor N., Bellini M. H., Endostatin neoadjuvant gene therapy extends survival in an orthotopic metastatic mouse model of renal cell carcinoma. Biomedicine and Pharmacotherapy 2012 66 237 241 2-s2.0-84860549930 10.1016/j.biopha.2011.11.002
18. Mao W., Kong J., Dai J., Huang Z.-Q., Wang D.-Z., Ni G.-B., Chen M.-L., Evaluation of recombinant endostatin in the treatment of atherosclerotic plaques and neovascularization in rabbits. Journal of Zhejiang University B 2010 11 8 599 607 2-s2.0-77955484157 10.1631/jzus.B1001011
19. Isobe K., Kuba K., Maejima Y., Suzuki J.-I., Kubota S., Isobe M., Inhibition of endostatin/collagen XVIII deteriorates left ventricular remodeling and heart failure in rat myocardial infarction model. Circulation Journal 2010 74 1 109 119 2-s2.0-75149142944 10.1253/circj.CJ-09-0486
20. Moulton K. S., Olsen B. R., Sonn S., Fukai N., Zurakowski D., Zeng X., Loss of collagen XVIII enhances neovascularization and vascular permeability in atherosclerosis. Circulation 2004 110 10 1330 1336 2-s2.0-4444257284 10.1161/01.CIR.0000140720.79015.3C
21. Moulton K. S., Heller E., Konerding M. A., Flynn E., Palinski W., Folkman J., Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation 1999 99 13 1726 1732 2-s2.0-0033528660
22. Li M., Liu F., Sun P., Gao Y., Chen H., Liu H., Wang M., Chen J., Zhao Y., Correlations between serum levels of vascular endothelial growth factor and endostatin with clinical pathological characteristics of patients with gastrointestinal cancers. Hepatogastroenterology 2012 59 1865 1868
23. Mo H. Y., Luo D. H., Qiu H. Z., Liu H., Chen Q. Y., Tang L. Q., Zhong Z. L., Huang P. Y., Zhao Z. J., Zhang C. Q., Zhang Y., Mai H. Q., Elevated serum endostatin levels are associated with poor survival in patients with advanced-stage nasopharyngeal carcinoma. Clinical Oncology 2013 25 308 317
24. Szarvas T., László V., Vom Dorp F., Reis H., Szendröi A., Romics I., Tilki D., Rübben H., Ergün S., Serum endostatin levels correlate with enhanced extracellular matrix degradation and poor patients' prognosis in bladder cancer. International Journal of Cancer 2012 130 12 2922 2929 2-s2.0-84859916431 10.1002/ijc.26343
25. Aref S., El-Sherbiny M., Azmy E., Goda T., Selim T., El-Refaie M., Twafik E., Elevated serum endostatin levels are associated with favorable outcome in acute myeloid leukemia. Hematology 2008 13 2 95 100 2-s2.0-48749127489 10.1179/102453308X315898
26. Oikonomou K. A., Kapsoritakis A. N., Kapsoritaki A. I., Manolakis A. C., Tiaka E. K., Tsiopoulos F. D., Tsiompanidis I. A., Potamianos S. P., Angiogenin, angiopoietin-1, angiopoietin-2, and endostatin serum levels in inflammatory bowel disease. Inflammatory Bowel Diseases 2011 17 4 963 970 2-s2.0-79952481259 10.1002/ibd.21410
27. Wathén K.-A., Ylikorkala O., Andersson S., Alfthan H., Stenman U.-H., Vuorela P., Maternal serum endostatin at gestational weeks 16-20 is elevated in subsequent pre-eclampsia but not in intrauterine growth retardation. Acta Obstetricia et Gynecologica Scandinavica 2009 88 5 593 598 2-s2.0-65649151085 10.1080/00016340902838293
28. Mitsuma W., Kodama M., Hanawa H., Ito M., Ramadan M. M., Hirono S., Obata H., Okada S., Sanada F., Yanagawa T., Kashimura T., Fuse K., Tanabe N., Aizawa Y., Serum endostatin in the coronary circulation of patients with coronary heart disease and its relation to coronary collateral formation. American Journal of Cardiology 2007 99 4 494 498 2-s2.0-33846826573 10.1016/j.amjcard.2006.09.095
29. Iribarren C., Herrinton L. J., Darbinian J. A., Tamarkin L., Malinowski D., Vogelman J. H., Orentreich N., Baer D., Does the association between serum endostatin, an endogenous anti-angiogenic protein, and acute myocardial infarction differ by race? Vascular Medicine 2006 11 1 13 20 2-s2.0-33646164164 10.1191/1358863x06vm654oa